14 pharmaceutical acquisitions in 2020

14 pharmaceutical acquisitions this year, as reported by Becker’s Hospital Review: 

Editor’s note: This is not an exhaustive list. Acquisitions are listed in chronological order. 

1. Eli Lilly to acquire small California biotech for $1.1 billion
   Eli Lilly acquired Dermira, a small Menlo Park, Calif.-based drugmaker that specializes in chronic skin conditions, for $1.1 billion.
2. Gilead acquires cancer biotech for $4.9B
   Gilead acquired Menlo Park, Calif.-based cancer biotech Forty Seven for $4.9 billion.
3. CVS to acquire St. Louis grocery chain’s pharmacy business
   CVS Pharmacy acquired all 110 of St. Louis-based grocery store chain Schnucks’ retail and specialty pharmacies.
4. J&J to acquire Momenta Pharma for $6.5B
   Johnson & Johnson bought Cambridge, Mass.-based Momenta Pharmaceuticals for $6.5 billion, a move to strengthen the drugmaker’s portfolio of autoimmune disease treatments.
5. Acadia Pharmaceuticals acquires Texas drugmaker for $52.5M
   Acadia Pharmaceuticals acquired Fort Worth, Texas-based biotech CerSci Therapeutics for $52.5 million, a move that broadened the San Diego-based drugmaker’s pain medication portfolio.
6. Nestle acquires Aimmune Therapeutics for $2.6B
   Nestle paid $2.6 billion to acquire Brisbane, Calif.-based Aimmune Therapeutics, a move that broadens the Swiss food company’s health science portfolio.
7. Bayer to acquire vitamin subscription company for $225M
   Bayer will purchase Care/of, an online vitamin and supplement provider, in efforts to expand its nutrition and wellness portfolio.
8. Gilead expands oncology portfolio, acquires Immunomedics for $21B
   Gilead purchased Immunomedics, a Morris Plains, N.J.-based cancer drugmaker, for $21 billion.
9. UnitedHealth acquires competitor to Amazon’s PillPack
   UnitedHealth Group acquired DivvyDose, a startup that delivers medications in presorted packages and competes with Amazon’s PillPack.
10. Bristol Myers Squibb acquires MyoKardia for $13B
    Bristol Myers Squibb inked a $13.1 billion deal to buy Brisbane, Calif.-based drugmaker MyoKardia, aiming to diversify its drug portfolio beyond oncology medicines. 
11. Rite Aid to acquire Seattle-based pharmacy chain for $95M
    Rite Aid acquired Seattle-based pharmacy chain Bartell Drugs for $95 million.
12. Bayer acquires gene therapy company for $4B
    Bayer bought gene therapy company Asklepios BioPharmaceutical, commonly known as AskBio, in a deal totaling $4 billion.
13. Merck to acquire COVID-19 drug developer for $425M
    Merck announced it will buy Rockville, Md.-based drugmaker OncoImmune for an upfront cash payment of $425 million to obtain rights to the drug it’s developing for patients hospitalized with severe and critical COVID-19.
14. Gilead to pay $1.4B for hepatitis drugmaker
    Gilead said it plans to buy German drugmaker MYR GmbH for $1.4 billion to gain access to its drug Hepcludex, which treats adults with chronic hepatitis delta virus infection.

More articles on pharmacy:
Pfizer COVID-19 vaccine doses get too cold, must be returned in 2 states
CVS begins $3M initiative to increase access to flu shots in underserved areas
Gilead to pay $1.4B for hepatitis drugmaker